Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion.

Whitt JD, Keeton AB, Gary BD, Sklar LA, Sodani K, Chen ZS, Piazza GA.

J Biomed Res. 2016 Mar;30(2):120-133. doi: 10.7555/JBR.30.20150108. Epub 2015 Nov 20.

2.

Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors.

Abdel-Rahman HM, Abdel-Aziz M, Tinsley HN, Gary BD, Canzoneri JC, Piazza GA.

Arch Pharm (Weinheim). 2016 Feb;349(2):104-11. doi: 10.1002/ardp.201500363. Epub 2015 Dec 20.

PMID:
26686665
3.

Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach.

Hassaan EA, Sigler SC, Ibrahim TM, Lee KJ, Cichon LK, Gary BD, Canzoneri JC, Piazza GA, Abadi AH.

Med Chem. 2016;12(5):472-7.

PMID:
26648332
4.

Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention.

Aboul-Fadl T, Al-Hamad SS, Lee K, Li N, Gary BD, Keeton AB, Piazza GA, Abdel-Hamid MK.

Med Chem Res. 2014 Sep;23(9):4177-4188.

5.

Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.

Abdel-Rahman HM, Abdel-Aziz M, Canzoneri JC, Gary BD, Piazza GA.

Arch Pharm (Weinheim). 2014 Sep;347(9):650-7. doi: 10.1002/ardp.201400083. Epub 2014 Jul 1.

PMID:
24985336
6.

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.

Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W.

PLoS One. 2014 Jun 4;9(6):e98370. doi: 10.1371/journal.pone.0098370. eCollection 2014.

7.

Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity.

Li N, Lee K, Xi Y, Zhu B, Gary BD, Ramírez-Alcántara V, Gurpinar E, Canzoneri JC, Fajardo A, Sigler S, Piazza JT, Chen X, Andrews J, Thomas M, Lu W, Li Y, Laan DJ, Moyer MP, Russo S, Eberhardt BT, Yet L, Keeton AB, Grizzle WE, Piazza GA.

Oncogene. 2015 Mar 19;34(12):1499-509. doi: 10.1038/onc.2014.94. Epub 2014 Apr 7.

8.

Synthesis of some dihydropyrimidine-based compounds bearing pyrazoline moiety and evaluation of their antiproliferative activity.

Awadallah FM, Piazza GA, Gary BD, Keeton AB, Canzoneri JC.

Eur J Med Chem. 2013;70:273-9. doi: 10.1016/j.ejmech.2013.10.003. Epub 2013 Oct 9.

9.

Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.

Abdel-Halim M, Keeton AB, Gurpinar E, Gary BD, Vogel SM, Engel M, Piazza GA, Boeckler FM, Hartmann RW, Abadi AH.

Bioorg Med Chem. 2013 Dec 1;21(23):7343-56. doi: 10.1016/j.bmc.2013.09.055. Epub 2013 Oct 1.

PMID:
24139845
10.

Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.

Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH, Moyer MP, Grizzle WE, Chang WC, Clapper ML, Piazza GA.

Mol Cancer Ther. 2013 Sep;12(9):1848-59. doi: 10.1158/1535-7163.MCT-13-0048. Epub 2013 Jun 26.

12.

Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.

El-Gamil DS, Ahmed NS, Gary BD, Piazza GA, Engel M, Hartmann RW, Abadi AH.

Arch Pharm (Weinheim). 2013 Jan;346(1):23-33. doi: 10.1002/ardp.201200334.

13.

Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives.

Ahmed NS, Ali AH, El-Nashar SM, Gary BD, Fajardo AM, Tinsley HN, Piazza GA, Negri M, Abadi AH.

Eur J Med Chem. 2012 Nov;57:329-43. doi: 10.1016/j.ejmech.2012.09.029. Epub 2012 Sep 29.

14.

A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.

Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, Piazza GA.

Cancer Prev Res (Phila). 2012 Jun;5(6):822-33. doi: 10.1158/1940-6207.CAPR-11-0559. Epub 2012 May 3. Erratum in: Cancer Prev Res (Phila). 2013 Jan;6(1):70.

15.

Four-component synthesis of 1,2-dihydropyridine derivatives and their evaluation as anticancer agents.

Abdel-Fattah MA, El-Naggar MA, Rashied RM, Gary BD, Piazza GA, Abadi AH.

Med Chem. 2012 May;8(3):392-400.

16.

Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs.

Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, Shevde LA, Samant RS, Dean-Colomb W, Piazza GA, Xi Y.

Oncogene. 2012 Nov 29;31(48):4979-86. doi: 10.1038/onc.2011.655. Epub 2012 Jan 30.

17.

Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.

Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA.

Cancer Prev Res (Phila). 2011 Aug;4(8):1275-84. doi: 10.1158/1940-6207.CAPR-11-0095. Epub 2011 Apr 19.

18.

Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.

Ahmed NS, Gary BD, Tinsley HN, Piazza GA, Laufer S, Abadi AH.

Arch Pharm (Weinheim). 2011 Mar;344(3):149-57. doi: 10.1002/ardp.201000236. Epub 2010 Dec 22.

19.

Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.

Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM, Abadi AH.

J Med Chem. 2011 Jan 27;54(2):495-509. doi: 10.1021/jm100842v. Epub 2010 Dec 28.

20.

A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors.

Ahmed NS, Gary BD, Piazza GA, Tinsley HN, Laufer S, Abadi AH.

Med Chem. 2010 Nov;6(6):374-87.

21.

Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.

Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA.

Cancer Prev Res (Phila). 2010 Oct;3(10):1303-13. doi: 10.1158/1940-6207.CAPR-10-0030. Epub 2010 Sep 28.

22.

A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model.

Zhang Y, Zhang J, Wang L, Quealy E, Gary BD, Reynolds RC, Piazza GA, Lü J.

Cancer Prev Res (Phila). 2010 Jul;3(7):885-95. doi: 10.1158/1940-6207.CAPR-09-0273. Epub 2010 Jun 29.

23.

NSAIDs: Old Drugs Reveal New Anticancer Targets.

Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary BD, Mathew B, Singh R, Grizzle WE, Reynolds RC.

Pharmaceuticals (Basel). 2010 May 25;3(5):1652-1667. Review.

24.

Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.

Abadi AH, Gary BD, Tinsley HN, Piazza GA, Abdel-Halim M.

Eur J Med Chem. 2010 Apr;45(4):1278-86. doi: 10.1016/j.ejmech.2009.10.046.

25.

Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.

Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA.

Mol Cancer Ther. 2009 Dec;8(12):3331-40. doi: 10.1158/1535-7163.MCT-09-0758.

26.

Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach.

Abadi AH, Abouel-Ella DA, Lehmann J, Tinsley HN, Gary BD, Piazza GA, Abdel-Fattah MA.

Eur J Med Chem. 2010 Jan;45(1):90-7. doi: 10.1016/j.ejmech.2009.09.029. Epub 2009 Sep 20.

27.

Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.

Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN, Keeton AB, Piazza GA.

Arzneimittelforschung. 2009;59(8):415-21.

28.

Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.

Abadi AH, Ibrahim TM, Abouzid KM, Lehmann J, Tinsley HN, Gary BD, Piazza GA.

Bioorg Med Chem. 2009 Aug 15;17(16):5974-82. doi: 10.1016/j.bmc.2009.06.063. Epub 2009 Jul 3.

29.

A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC.

Cancer Prev Res (Phila). 2009 Jun;2(6):572-80. doi: 10.1158/1940-6207.CAPR-09-0001. Epub 2009 May 26.

30.

Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.

Manne U, Gary BD, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE.

Clin Cancer Res. 2001 Nov;7(11):3495-503.

31.

The cost of home air-fluidized therapy for pressure sores. A randomized controlled trial.

Strauss MJ, Gong J, Gary BD, Kalsbeek WD, Spear S.

J Fam Pract. 1991 Jul;33(1):52-9.

PMID:
2056290

Supplemental Content

Support Center